| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $0 ) |
| | 2026 | 2024 | ACEPRE, LLC | 6439 GARNERS FERRY | COLUMBIA | SC | 29209-1638 | RICHLAND | USA | UT1AA030690 | Developing natural compound emodin as a therapy for alcoholic cardiomyopathy | 000 | 2 | NIH | 6/23/2026 | $0 |
|
| Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2024 | ACEPRE, LLC | 6439 GARNERS FERRY | COLUMBIA | SC | 29209-1638 | RICHLAND | USA | R41HL172481 | Develop natural compound emodin as a novel therapy for calcific aortic valve disease | 000 | 1 | NIH | 10/12/2024 | $0 |
| | 2025 | 2024 | ACEPRE, LLC | 6439 GARNERS FERRY | COLUMBIA | SC | 29209-1638 | RICHLAND | USA | R41HL172481 | Develop natural compound emodin as a novel therapy for calcific aortic valve disease | 001 | 1 | NIH | 8/11/2025 | $0 |
| | 2025 | 2022 | ACEPRE, LLC | 6439 GARNERS FERRY | COLUMBIA | SC | 29209-1638 | RICHLAND | USA | R41AG081124 | The development of a multifunctional nanoenzyme for AD treatment | 000 | 1 | NIH | 12/23/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $1,558,240 ) |
| | 2024 | 2024 | ACEPRE, LLC | 6439 GARNERS FERRY | COLUMBIA | SC | 29209-1638 | RICHLAND | USA | R41HL172481 | Develop natural compound emodin as a novel therapy for calcific aortic valve disease | 000 | 1 | NIH | 9/16/2024 | $299,953 |
| | 2024 | 2024 | ACEPRE, LLC | 6439 GARNERS FERRY | COLUMBIA | SC | 29209-1638 | RICHLAND | USA | UT1AA030690 | Developing natural compound emodin as a therapy for alcoholic cardiomyopathy | 000 | 2 | NIH | 2/29/2024 | $461,518 |
| | 2024 | 2024 | ACEPRE, LLC | 6439 GARNERS FERRY | COLUMBIA | SC | 29209-1638 | RICHLAND | USA | R41AI174362 | Targeting macrophage maladaptation for bacterial sepsis treatment | 000 | 2 | NIH | 5/24/2024 | $297,328 |
| | 2024 | 2024 | ACEPRE, LLC | 6439 GARNERS FERRY | COLUMBIA | SC | 29209-1638 | RICHLAND | USA | R41AG087769 | Develop a novel strategy to deliver N-acetylcysteine for AD treatment | 000 | 1 | NIH | 9/12/2024 | $499,441 |
| | 2024 | 2021 | ACEPRE, LLC | 6439 GARNERS FERRY | COLUMBIA | SC | 29209-1638 | RICHLAND | USA | R41AI157378 | Use novel natural compound Sparstolonin B to treat bacterial sepsis | 000 | 1 | NIH | 1/9/2024 | $0 |
| | 2024 | 2021 | ACEPRE, LLC | 6439 GARNERS FERRY | COLUMBIA | SC | 29209-1638 | RICHLAND | USA | R41CA254500 | A novel polymer-metal nanocomplex for ovarian cancer treatment | 000 | 1 | NIH | 10/13/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $756,822 ) |
| | 2023 | 2023 | ACEPRE, LLC | 6439 GARNERS FERRY RD BLDG 1 C53 | COLUMBIA | SC | 29209-1638 | RICHLAND | USA | UT1AA030690 | Developing natural compound emodin as a therapy for alcoholic cardiomyopathy | 000 | 1 | NIH | 3/14/2023 | $456,840 |
| | 2023 | 2023 | ACEPRE, LLC | 6439 GARNERS FERRY RD BLDG 1 C53 | COLUMBIA | SC | 29209-1638 | RICHLAND | USA | R41AI174362 | Targeting macrophage maladaptation for bacterial sepsis treatment | 000 | 1 | NIH | 6/15/2023 | $299,982 |
| | 2023 | 2020 | ACEPRE, LLC | 6439 GARNERS FERRY RD BLDG 1 C53 | COLUMBIA | SC | 29209-1638 | RICHLAND | USA | R43AT011171 | Development of Dietary Quercetin to Treat Muscle Wasting Disorders | 000 | 1 | NIH | 8/8/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $299,628 ) |
| | 2022 | 2022 | ACEPRE, LLC | 6439 GARNERS FERRY RD BLDG 1 C53 | COLUMBIA | SC | 29209-1638 | RICHLAND | USA | R41AG081124 | The development of a multifunctional nanoenzyme for AD treatment | 000 | 1 | NIH | 9/23/2022 | $299,628 |
|
| Issue Date FY: 2021 ( Subtotal = $744,803 ) |
| | 2021 | 2021 | ACEPRE, LLC | 6439 GARNERS FERRY RD BLDG 1 C53 | COLUMBIA | SC | 29209-1638 | RICHLAND | USA | R41CA254500 | A novel polymer-metal nanocomplex for ovarian cancer treatment | 000 | 1 | NIH | 12/8/2020 | $392,803 |
| | 2021 | 2021 | ACEPRE, LLC | 6439 GARNERS FERRY RD BLDG 1 C53 | COLUMBIA | SC | 29209-1638 | RICHLAND | USA | R41AI157378 | Use novel natural compound Sparstolonin B to treat bacterial sepsis | 000 | 1 | NIH | 2/5/2021 | $300,000 |
| | 2021 | 2021 | ACEPRE, LLC | 6439 GARNERS FERRY RD BLDG 1 C53 | COLUMBIA | SC | 29209-1638 | RICHLAND | USA | R43AT011171 | Development of Dietary Quercetin to Treat Muscle Wasting Disorders | 000 | 1 | NIH | 5/5/2021 | $52,000 |
| | 2021 | 2018 | ACEPRE, LLC | 6439 GARNERS FERRY RD BLDG 1 C53 | COLUMBIA | SC | 29209-1638 | RICHLAND | USA | R41AT009964 | Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil | 000 | 1 | NIH | 12/15/2020 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $299,998 ) |
| | 2020 | 2020 | ACEPRE, LLC | 6439 GARNERS FERRY RD BLDG 1 C53 | COLUMBIA | SC | 29209-1638 | RICHLAND | USA | R43AT011171 | Development of Dietary Quercetin to Treat Muscle Wasting Disorders | 000 | 1 | NIH | 9/9/2020 | $299,998 |
|
| Issue Date FY: 2019 ( Subtotal = $38,933 ) |
| | 2019 | 2019 | ACEPRE, LLC | 6439 GARNERS FERRY RD BLDG 1 C53 | COLUMBIA | SC | 29209-1638 | RICHLAND | USA | R41AT009964 | Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil | 001 | 1 | NIH | 1/31/2019 | $38,933 |
| | 2019 | 2018 | ACEPRE, LLC | 6439 GARNERS FERRY RD BLDG 1 C53 | COLUMBIA | SC | 29209-1638 | RICHLAND | USA | R41AT009964 | Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil | 000 | 1 | NIH | 10/23/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $261,212 ) |
| | 2018 | 2018 | ACEPRE, LLC | 6439 GARNERS FERRY RD BLDG 1 C53 | COLUMBIA | SC | 29209-1638 | RICHLAND | USA | R41AT009964 | Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil | 000 | 1 | NIH | 9/20/2018 | $261,212 |
|
|
